Spectrum Puts Its Eggs In One Basket: Folotyn, Beleodaq To Share Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
With Spectrum’s Beleodaq’s accelerated approval for peripheral T-cell lymphoma, FDA rolls Folotyn accelerated approval requirement into one post-marketing trial that will provide answers on both drugs – including which is better against standard of care.
You may also be interested in...
Accelerated Approval: Acrotech’s Confirmatory Trial For Folotyn, Beleodaq More Than A Decade Behind Schedule
Under sponsor's current timetable, a single, two-part trial for pralatrexate and belinostat would not complete until 2030, resulting in respective delays of 21 and 16 years in confirming or refuting clinical benefit following accelerated approval. ODAC will discuss Acrotech’s delayed confirmatory trial program on 16 November.
Onxeo Plans Clinical Trials For Three Phase III Orphan Oncologics
The year-old pan-European biotech is targeting advanced liver cancer, severe mucositis and the rare cancer, peripheral T-cell lymphoma, for its first products in the orphan oncology niche.
CDER Builds Strong Foundation Of NMEs For 2014 As Approval Total Hits 20
Pharmaceutical Approvals Monthly takes stock of FDA’s performance at mid-year: CDER only needs to clear eight more novel agents to top 2013 in new molecular entity and novel biologic approvals, and priority and orphan drugs make up a higher portion of novel approvals than in recent years.